Protecting the Body from Radiation Exposure
Official title: Non-Clinical Pharmacology of CX-01
Funded at Ceramedix Holding, LLC · NIH-11026444 · Data updated 2026-11-12
This project is developing a new medicine called CX-01 to help protect people from the harmful effects of radiation exposure, especially in the digestive system.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ceramedix Holding, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2014 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $992,960 |
| NIH project number | 5R44AI106283-08 |
| Project ID | NIH-11026444 on NIH RePORTER |
Who could benefit from this research
✓Could help
Future patients who have been exposed to dangerous levels of radiation, particularly those at risk of severe digestive system damage, would be the target beneficiaries of this medicine.
✕Less likely to help
Patients who have not been exposed to radiation or whose radiation sickness primarily affects other body systems might not directly benefit from this specific treatment.
What this research studies
When people are exposed to radiation, it can cause serious damage to their blood-forming cells and digestive system, which can be life-threatening. While some treatments exist for blood-related radiation sickness, there isn't an effective medicine yet for digestive system damage. Our team is working on CX-01, a special antibody fragment designed to protect cells in the digestive tract and other organs from radiation injury. By targeting and disrupting specific cell signals, CX-01 aims to prevent cell death and reduce the severity of radiation sickness.
Why it matters
Potential benefit: If successful, CX-01 could become the first effective medicine to protect the digestive system from severe radiation damage, potentially saving lives after radiation exposure.
How similar studies have gone: While existing drugs have shown promise for blood-related radiation sickness in preclinical models, CX-01 represents a novel approach specifically for digestive system damage, building on extensive data showing that disrupting the ceramide signaling pathway can protect against radiation injury.
Where this research is happening
-
Ceramedix Holding, LLC
New York, United States Active
Researchers
- Principal investigator: Vid, Galina — Ceramedix Holding, LLC
- Study coordinator: Vid, Galina
Related research
Other NIH-funded projects on the same topics.
-
Developing a new treatment to protect against radiation damage
This study is testing a new treatment called CX-01 that aims to protect blood vessels from damage caused by radiation, which could help people who have been exposed to harmful radiation avoid serious health issues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.